Zembrace Symtouch Generic Name & Formulations
Sumatriptan (as succinate) 3mg/0.5mL; soln for SC inj.
Selective 5-HT1B/1D receptor agonist.
Single-dose prefilled autoinjector—4
Mechanism of Action
Sumatriptan binds with high affinity to human cloned 5-HT1B/1D receptors. Sumatriptan presumably exerts its therapeutic effects in the treatment of migraine headache through agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels and sensory nerves of the trigeminal system, which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.
Zembrace Symtouch Indications
Acute treatment of migraine with or without aura.
Limitations of Use
Confirm diagnosis; reconsider if no response after treatment. Not for prevention of migraine attacks.
Zembrace Symtouch Dosage and Administration
≥18yrs: 3mg by SC inj. Reevaluate if no response. Max cumulative dose: 12mg in 24hrs with each dose separated by at least 1hr. May also be given at least 1hr following another sumatriptan product.
<18yrs: not recommended.
Zembrace Symtouch Contraindications
Ischemic coronary artery disease (CAD) (eg, angina, history of MI, silent ischemia). Coronary artery vasospasm (including Prinzmetal's angina). Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders. History of stroke or TIA. History of hemiplegic or basilar migraine. Peripheral vascular disease. Ischemic bowel disease. Uncontrolled hypertension. Within 24hrs of ergot-type drugs (eg, methysergide, dihydroergotamine) or other 5-HT1 agonists. During or within 2 weeks of an MAO-A inhibitor. Severe hepatic impairment.
Zembrace Symtouch Boxed Warnings
Zembrace Symtouch Warnings/Precautions
Avoid excessive use. Exclude underlying neurologic or cardiovascular disease, supervise 1st dose, and consider monitoring ECG in patients with multiple risk factors (eg, increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD). Monitor BP, cardiovascular function in long-term intermittent use. Discontinue if serious arrhythmias or cerebrovascular events occur or if serotonin syndrome is suspected. Peripheral or GI vascular ischemia and infarction following other 5-HT1 agonists. History, or risk of seizures. Elderly. Pregnancy. Nursing mothers (avoid nursing for 12 hours after treatment).
Zembrace Symtouch Pharmacokinetics
Renal. Half-life: 115 ± 19 minutes.
Zembrace Symtouch Interactions
See Contraindications. Increased risk of serotonin syndrome with SSRIs, SNRIs, tricyclics, or MAO inhibitors.
Zembrace Symtouch Adverse Reactions
Inj site reactions, tingling, dizziness/vertigo, warm/hot/burning sensation, feeling of heaviness/tightness, pressure sensation, flushing, numbness/paresthesia; medication overuse headache; rare: serious cardiac and cerebrovascular events (including fatalities), vision loss, hypertensive crisis, hypersensitivity reactions.
Zembrace Symtouch Clinical Trials
Zembrace Symtouch Note
Zembrace Symtouch Patient Counseling